Development of Zevalin and future prospect of radioimmunotherapy

Abstract

Zevalin, the first approved radioimmunotherapeutic agent for Non-hodgkin's lymphoma, is not only highly effective but also kind treatment even for elderly patients. In this review, we summarize development of Zevalin and future prospect of radioimmunotherapy (RIT), and introduce our candidate as a novel radioimmunotherapeutic agent for NSCLC treatment. Prospective selection of patients responds to RIT will be essential for approval in oncology.